References and Notes
- 1
Navarrete-Vázquez G.
Yepez-Mulia L.
Hernández-Campos A.
Tapia A.
Hernández-Luis F.
Cedillo R.
González J.
Martínez-Fernández M.
Martínez-Grueiro M.
Castillo R.
Bioorg. Med. Chem.
2003,
11:
4615
-
2a
Özden S.
Atabey D.
Yýldýz S.
Göker H.
Bioorg. Med. Chem.
2005,
13:
1587
-
2b
Palmer PJ.
Trigg RB.
Warrington JV.
J. Med. Chem.
1971,
14:
248
-
3a
Andrzejewska M.
Yépez-Mulia L.
Cedillo-Rivera R.
Tapia A.
Vilpo L.
Vilpo J.
Kazimierczuk Z.
Eur. J. Med. Chem.
2002,
37:
973
-
3b
Hall IH.
Peaty NJ.
Henry
JR.
Easmon J.
Heinisch G.
Purstinger G.
Arch.
Pharm. (Weinheim, Ger.)
1999,
332:
115
- 4
Bénéteau V.
Besson T.
Guillard J.
Léonce S.
Pfeiffer B.
Eur. J. Med. Chem.
1999,
34:
1053
- 5 Kücükbay H.,
Durmaz R., Orhan E., Günal S.; Farmaco; 2003, 58: 431
-
6a
Benazzouz A.
Boraud T.
Dubédat P.
Boireau A.
Stutzmann J.-M.
Gross C.
Eur.
J. Pharmacol.
1995,
284:
299
-
6b
Jimonet P.
Audiau F.
Barreau M.
Blanchard
J.-C.
Boireau A.
Bour Y.
Coléno M.-A.
Doble A.
Doerflinger G.
Huu CD.
Donat M.-H.
Duchesne JM.
Ganil P.
Guérémy C.
Honoré E.
Just B.
Kerphirique R.
Gontier S.
Hubert P.
Laduron PM.
Blevec JL.
Meunier M.
Miquet J.-M.
Nemecek C.
Pasquet M.
Piot O.
Pratt J.
Rataud J.
Reibaud M.
Stutzmann J.-M.
Mignani S.
J.
Med. Chem.
1999,
42:
2828
-
7a
Hamdouchi C.
de Blas J.
del Prado M.
Gruber J.
Heinz BA.
Vance L.
J.
Med. Chem.
1999,
42:
50
-
7b
Girardet J.-L.
Townsend LB.
J. Org. Chem.
1999,
64:
4169
-
7c
Yeh C.-M.
Tung C.-L.
Sun C.-M.
J.
Comb. Chem.
2000,
2:
341
-
7d
Chen JJ.
Wei Y.
Drach JC.
Townsend LB.
J.
Med. Chem.
2000,
43:
2449
-
7e
Tumelty D.
Cao K.
Holmes CP.
Org.
Lett.
2001,
3:
83
-
7f
Mann J.
Baron A.
Opoku-Boahen Y.
Johansson E.
Parkinson G.
Kelland LR.
Neidle S.
J.
Med. Chem.
2001,
44:
138
-
7g
Raju B.
Nguyen N.
Holland GW.
J.
Comb. Chem.
2002,
4:
320
-
7h
Akamatsu H.
Fukase K.
Kusumoto S.
J.
Comb. Chem.
2002,
4:
475
-
7i
Hoesl CE.
Nefzi A.
Houghten RA.
J. Comb. Chem.
2003,
5:
155
-
7j
Vourloumis D.
Takahashi M.
Simonsen KB.
Ayida BK.
Barluenga S.
Winters GC.
Hermann T.
Tetrahedron
Lett.
2003,
44:
2807
-
8a
Chua M.-S.
Shi D.-F.
Wrigley S.
Bradshaw TD.
Hutchinson I.
Shaw PN.
Barrett DA.
Stanley LA.
Stevens MFG.
J.
Med. Chem.
1999,
42:
381
-
8b
Kashiyama E.
Hutchinson I.
Chua M.-S.
Stinson
SF.
Phillips LR.
Kaur G.
Sausville EA.
Bradshaw TD.
Westwell AD.
Stevens MFG.
J. Med. Chem.
1999,
42:
4172
-
8c
Hutchinson I.
Chua M.-S.
Browne
HL.
Trapani V.
Bradshaw TD.
Westwell AD.
Stevens MFG.
J. Med.
Chem.
2001,
44:
1446
-
8d
Leng W.
Zhou Y.
Xu Q.
Liu J.
Macromolecules
2001,
34:
4774
-
8e
Hutchinson I.
Jennings SA.
Vishnuvajjala
BR.
Westwell AD.
Stevens MFG.
J. Med.
Chem.
2002,
45:
744
- 9
Kochi M.
Green
Reaction Media for Organic Synthesis
Blackwell;
Oxford:
2005.
- 10
Seddon KR.
Nature
(London)
2003,
2:
363
- 11
Catalytic
Oxidations with Hydrogen Peroxide as Oxidant
Strukul G.
Kluwer Academic;
Dordrecht:
1992.
- 12
Noyori R.
Aoki M.
Sato K.
Chem.
Commun.
2003,
1977
-
13a
Bahrami K.
Tetrahedron Lett.
2006,
47:
2009
-
13b
Khodaei MM.
Bahrami K.
Khedri M.
Can. J. Chem.
2007,
58:
7
-
13c
Khodaei MM.
Bahrami K.
Karimi A.
Synthesis
2008,
1682
-
13d
Bahrami K.
Khodaei MM.
Kamali S.
Chin.
J. Chem.
2008,
26:
1119
- 14
Bahrami K.
Khodaei MM.
Kavianinia I.
Synthesis
2007,
547
- 15
Eynde JJV.
Delfosse F.
Lor P.
Haverbeke YV.
Tetrahedron
1995,
51:
5813
- 16
Das B.
Holla H.
Srinivas Y.
Tetrahedron
Lett.
2007,
48:
61
- 17
Wang Y.
Sarris K.
Sauer DR.
Djuric SW.
Tetrahedron Lett.
2006,
47:
4823
- 18
Ben-Alloum A.
Bougrin K.
Soufiaoui M.
Tetrahedron Lett.
2003,
44:
5935
- 19
Gogoi P.
Konwar D.
Tetrahedron Lett.
2006,
47:
79
- 20
Ben-Alloum A.
Bakkas S.
Souflaoui M.
Tetrahedron Lett.
1998,
39:
4481
- 21
Bougrin K.
Loupy A.
Souflaoui M.
Tetrahedron
1998,
54:
8055
- 22
Hein DW.
Alheim RJ.
Leavitt JJ.
J. Am. Chem. Soc.
1957,
79:
427
- 23
Ben-Alloum A.
Bakkas S.
Souflaoui M.
Tetrahedron Lett.
1997,
38:
6395
- 25
Charlton PT.
Mlalipliant GK.
Oxley P.
Peak DA.
J. Chem. Soc.
1951,
485
- 26
George B.
Papadopoulos EP.
J. Org. Chem.
1977,
42:
441
24 Ferric nitrate, hydrogen peroxide
(30%) as well as all the aromatic aldehydes, 1,2-phenylenediamine
derivatives and 2-aminothiophenol employed as substrates are commer-cially
available and were used without further purification. The concentration
of the commercial 30% H2O2 solution was
checked iodometrically prior to use.
General
procedure for the Synthesis of Benzimidazoles and Benzothiazoles:
A mixture of 1,2-phenylenediamine (1 mmol), aryl aldehyde (1 mmol),
H2O2 (30%, 4 mmol, 0.4 mL) and Fe(NO3)3˙9
H2O (0.1 mmol, 0.04 g) was heated at 50 ˚C for
the appropriate time as mentioned in Table 2. After completion of
the reaction, the reaction mixture was dissolved in EtOH (10 mL)
and then poured into ice-water (30 mL). The pure solid product was
filtered, washed with ice-water and subsequently dried. An identical
procedure was employed using 2-aminothiophenol (1 mmol), aryl aldehyde
(1 mmol) in the presence of 30% H2O2 (4
mmol) and Fe(NO3)3.9 H2O (0.1 mmol)
for the synthesis of benzothiazoles (Table 4).
Spectroscopic and Physical Data for Selected Compounds:
2-Phenyl-1
H
-benzimidazole: mp 290-291 ˚C
(lit.
[¹8]
292 ˚C). ¹H
NMR (200 MHz, DMSO-d
6): δ = 7.19-7.23
(m, 2 H), 7.51-7.61 (m, 5 H), 8.16-8.21 (m, 2
H), 12.91 (br, 1 H, NH). ¹³C NMR (50
MHz, DMSO-d
6): δ = 120.1,
123.0, 127.0, 127.3, 129.8, 130.8, 131.0, 152.1.
2-(2-Chlorophenyl)-1
H
-benzimidazole: mp 232-234 ˚C (lit.
[¹8]
234 ˚C). ¹H
NMR (200 MHz, DMSO-d
6): δ = 7.26-7.32
(m, 2 H), 7.56-7.73 (m, 5 H), 7.93-7.96 (m, 1
H), 12.78 (br, 1 H, NH). ¹³C NMR (50
MHz, DMSO-d
6): δ = 112.1, 119.4,
122.1, 123.1, 127.8, 130.3, 130.7, 131.6, 132.4, 149.4.
2-(4-Hydroxyphenyl)-1
H
-benzimidazole: mp 276-278 ˚C (lit.
[²5]
279 ˚C). ¹H
NMR (200 MHz, DMSO-d
6): δ = 5.04
(br, 1 H, OH), 6.91 (d, J = 8.7
Hz, 2 H), 7.12-7.21 (m, 2 H), 7.48-7.57 (m, 2
H), 7.97 (d, J = 8.7 Hz, 2 H),
10.02 (br, 1 H, NH). ¹³C NMR (50 MHz,
DMSO-d
6): δ = 120.1,
121.4, 125.9, 127.6, 133.9, 144.2, 157.2, 165.
2-(3-Bromophenyl)benzothiazole: mp 91-93 ˚C. ¹H
NMR (200 MHz, DMSO-d
6): δ = 7.34-7.66
(m, 4 H), 7.91-8.12 (m, 3 H), 8.29-8.31 (m, 1
H). ¹³C NMR (50 MHz, DMSO-d
6): δ = 122.1,
123.5, 123.8, 126, 126.6, 126.9, 130.6, 130.9, 134.2, 135.4, 135.8,
154.3, 166.5. Anal. Calcd for C13H8NSBr: C,
53.81; H, 2.70; N, 4.83; S, 11.05. Found: C, 54.00; H, 2.70; N,
5.20; S, 11.10.
2-(4-Formylphenyl)benzothiazole:
mp 135-136 ˚C. ¹H NMR (200
MHz, DMSO-d
6): δ = 7.39-7.56
(m, 2 H), 7.90-8.26 (m, 6 H), 10.06 (s, 1 H).¹³C
NMR (50 MHz, DMSO-d
6): δ = 122.2,
124.1, 126.0, 126.3, 127.1, 128.4, 130.7, 135.8, 138.0, 139.1, 154.5,
191.9. Anal. Calcd for C14H9NSO: C, 70.27;
H, 3.79; N, 5.85; S, 13.41. Found: C, 70.00; H, 3.70; N, 6.10; S,
13.20.
2-(4-Methylphenyl)benzothiazole:
mp 85-86 ˚C (lit.
[²6]
85-86 ˚C). ¹H
NMR (200 MHz, DMSO-d
6): δ = 2.41
(s, 3 H), 7.24-7.48 (m, 4 H), 7.86-8.04 (m, 4
H). ¹³C NMR (50 MHz, DMSO-d
6): δ = 22.0,
122.0, 123.5, 125.5, 126.7, 127.9, 130.2, 131.3, 135.4, 141.9, 154.6,
168.7.